- Home
- LMB vs ELVN Comparison
LMB vs ELVN Comparison
Compare LMB & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- ELVN
- Stock Information
- Founded
- LMB 1901
- ELVN 2016
- Country
- LMB United States
- ELVN United States
- Employees
- LMB N/A
- ELVN N/A
- Industry
- LMB Engineering & Construction
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- ELVN Health Care
- Exchange
- LMB Nasdaq
- ELVN Nasdaq
- Market Cap
- LMB 1.2B
- ELVN 1.2B
- IPO Year
- LMB 2014
- ELVN 2020
- Fundamental
- Price
- LMB $89.97
- ELVN $20.19
- Analyst Decision
- LMB Strong Buy
- ELVN Strong Buy
- Analyst Count
- LMB 3
- ELVN 5
- Target Price
- LMB $140.67
- ELVN $41.20
- AVG Volume (30 Days)
- LMB 242.0K
- ELVN 563.5K
- Earning Date
- LMB 11-04-2025
- ELVN 11-12-2025
- Dividend Yield
- LMB N/A
- ELVN N/A
- EPS Growth
- LMB 35.95
- ELVN N/A
- EPS
- LMB 2.92
- ELVN N/A
- Revenue
- LMB $552,919,000.00
- ELVN N/A
- Revenue This Year
- LMB $28.57
- ELVN N/A
- Revenue Next Year
- LMB $14.48
- ELVN $20.05
- P/E Ratio
- LMB $31.00
- ELVN N/A
- Revenue Growth
- LMB 8.06
- ELVN N/A
- 52 Week Low
- LMB $63.02
- ELVN $13.30
- 52 Week High
- LMB $154.05
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- LMB 35.27
- ELVN 52.19
- Support Level
- LMB $87.55
- ELVN $19.02
- Resistance Level
- LMB $98.07
- ELVN $20.66
- Average True Range (ATR)
- LMB 4.55
- ELVN 1.04
- MACD
- LMB 0.01
- ELVN 0.10
- Stochastic Oscillator
- LMB 13.47
- ELVN 71.76
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.